文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

平衡晶体液与生理盐水在重症患者液体复苏中的比较:系统评价与Meta分析

Fluid resuscitation with balanced crystalloids versus normal saline in critically ill patients: a systematic review and meta-analysis.
PubMed 文献 · Scand J Trauma Resusc Emerg Med · 2022-04-18
一句话结论重症患者中平衡晶体液与生理盐水总体死亡率无显著差异,但非创伤性脑损伤患者用平衡晶体液死亡风险更低,创伤性脑损伤患者用生理盐水死亡风险更低。

该系统评价与Meta分析检索PubMed、Embase和CENTRAL,纳入8项比较ICU患者使用平衡晶体液与生理盐水的研究,共35,456例患者。主要终点为最长随访死亡率,平衡晶体液与生理盐水无显著差异(RR 0.96,95%CI 0.92-1.01)。亚组分析显示创伤性脑损伤患者接受生理盐水死亡率更低(RR 1.25,95%CI 1.02-1.54),非创伤性脑损伤患者平衡晶体液死亡率更低(RR 0.94,95%CI 0.90-0.99)。中重度急性肾损伤(RR 0.96,95%CI 0.90-1.01)和新增肾脏替代治疗(RR 0.94,95%CI 0.84-1.04)均无显著差异。作者认为平衡晶体液可能不改善重症患者死亡率、急性肾损伤发生率和肾脏替代治疗使用,但需大规模严格随机试验进一步验证。

要点

  • 8项研究共35,456例ICU患者,平衡晶体液与生理盐水总体死亡率无显著差异(RR 0.96,95%CI 0.92-1.01)。
  • 创伤性脑损伤亚组中,接受生理盐水者死亡率更低(RR 1.25,95%CI 1.02-1.54)。
  • 非创伤性脑损伤患者中,平衡晶体液死亡率低于生理盐水(RR 0.94,95%CI 0.90-0.99)。
  • 中重度急性肾损伤发生率无显著差异(RR 0.96,95%CI 0.90-1.01)。
  • 新增肾脏替代治疗无显著差异(RR 0.94,95%CI 0.84-1.04)。

适用人群与场景

  • ICU患者,尤其需要复苏的患者。
  • 亚组包括创伤性脑损伤患者和非创伤性脑损伤患者。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入8项比较平衡晶体液与生理盐水在ICU患者中应用的研究,共35,456例患者。
  • 主要终点:最长随访死亡率,平衡晶体液与生理盐水无显著差异(RR 0.96,95%CI 0.92-1.01)。
  • 亚组分析:创伤性脑损伤患者接受生理盐水死亡率更低(RR 1.25,95%CI 1.02-1.54);非创伤性脑损伤患者平衡晶体液死亡率更低(RR 0.94,95%CI 0.90-0.99)。
  • 次要终点:中重度急性肾损伤无显著差异(RR 0.96,95%CI 0.90-1.01);新增肾脏替代治疗无显著差异(RR 0.94,95%CI 0.84-1.04)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,采用Cochrane协作网工具评估偏倚风险。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与生理盐水相比,平衡晶体液可能不改善重症患者的死亡率、急性肾损伤发生率和肾脏替代治疗使用。
  • 作者认为,平衡晶体液降低非创伤性脑损伤患者的死亡风险,但增加创伤性脑损伤患者的死亡风险。
  • 作者建议需要大规模严格设计的随机试验,尤其是针对特定患者群体。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intravenous fluids are used commonly for almost all intensive care unit (ICU) patients, especially for patients in need of resuscitation. The selection and use of resuscitation fluids may affect the outcomes of patients; however, the optimal resuscitative fluid remains controversial.

METHODS: We systematically searched PubMed, Embase, and CENTRAL. Studies comparing balanced crystalloids and normal saline in ICU patients were selected. We used the Cochrane Collaboration tool to assess the risk of bias in studies. The primary outcome was mortality at the longest follow-up. Secondary outcomes included the incidence of acute kidney injury (AKI) and new renal replacement therapy (RRT).

RESULTS: A total of 35,456 patients from eight studies were included. There was no significant difference between balanced crystalloid solutions and saline in mortality (risk ratio [RR]: 0.96; 95% confidence interval [CI]:0.92-1.01). The subgroup analysis with traumatic brain injury (TBI) showed lower mortality in patients receiving normal saline (RR:1.25; 95% CI 1.02-1.54). However, in patients with non-TBI, balanced crystalloid solutions achieved lower mortality than normal saline (RR: 0.94; 95% CI 0.90-0.99). There was no significant difference in moderate to severe AKI (RR: 0.96; 95% CI 0.90-1.01) or new RRT (RR: 0.94; 95% CI 0.84-1.04).

CONCLUSIONS: Compared with normal saline, balanced crystalloids may not improve the outcomes of mortality, the incidence of AKI, and the use of RRT for critically ill patients. However, balanced crystalloids reduce the risk of death in patients with non-TBI but increase the risk of death in those with TBI. Large-scale rigorous randomized trials with better designs are needed, especially for specific patient populations.

来源:Scand J Trauma Resusc Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Dong WH, Yan WQ, Song X, et al. Fluid resuscitation with balanced crystalloids versus normal saline in critically ill patients: a systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2022. PMID: 35436929. doi:10.1186/s13049-022-01015-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。